The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alice Tseng, PharmD
Toronto General Hospital
Study Director - Cecile Tremblay, MD
Centre hospitalier de l'Université de Montréal (CHUM)
Principal Investigator - Line Labbé, PhD
Faculté de pharmacie, Université de Montréal
Principal Investigator - Nancy L Sheehan, B.Pharm, MSc
Faculté de pharmacie, Université de Montréal
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centre Hospitalier de L'Université de Montréal
Montreal, Quebec, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2012
- Primary completion
- 30 Apr 2013
- Completion
- 28 Feb 2014
- Last update posted
- 26 Jan 2018
- Registered enrollment
- 11
- Registry id
- NCT01627717
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.